Top Tech Companies (1,917)
Don't see your company?
Create a company profile
Gladstone's mission is to drive a new era of discovery in disease-oriented science and to mentor tomorrow’s leaders in an inspiring and diverse environment. Although Gladstone shares traits with other top life science organizations, we pride ourselves on taking uncommon scientific paths to overcoming disease. Our investigators are selected to become authorities in leading or creating new fields, and we work to provide them with resources to explore bold new thoughts, form effective scientific teams, and create or master emerging research technologies that accelerate progress—Gladstone’s special recipe for success that has yielded some of the most important biomedical advances of our time. Our three disease-focused institutes constitute the core of our discovery engine, but do not operate in isolation. We are seizing unprecedented opportunities for “convergence”—defined as the blending of intellectual and physical assets from multiple scientific disciplines and fields to speed the discovery process in our attack on unsolved health problems that affect almost every human family.
Adamis Pharmaceuticals is a biopharmaceutical company developing therapeutics for respiratory diseases and cancer.
Catalent Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent supports our partners in introducing 200 new products and manufacturing over 70 billion doses each year. Since becoming a publicly traded company in 2014, we have grown to become a community of approximately 19,000+ workers who support over 7,000 products for over 1,000 customers around the world. We share a common goal: to put patients first and help people around the world live better and healthier lives. Catalyst + Talent. Our name combines these ideas. From drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. We have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging results. more products. better treatments. reliably supplied.™ Your talents, ideas, and passion are essential to our mission: to develop, manufacture, and supply products that help people live better, healthier lives. Join us! Catalent hires people with a passion to make a difference to the health of millions of people globally. Your expertise, coupled with Catalent’s advanced technologies and collaboration with thousands of innovative pharmaceutical, biotech, and healthcare companies, will help bring life-enhancing products to life. Grow with us. Be challenged. Make a personal impact. Visit https://careers.catalent.com/us/en to explore career opportunities
AlgiKnit is creating eco-conscious, renewable yarns for the circular economy. We’re developing durable yet rapidly degradable yarns from kelp, one of the most regenerative organisms on the planet. Our material is built for everyone: a functional and accessible resource without environmental harm. We’re envisioning a future where the textile industry operates in a closed-loop product lifecycle, utilizing materials with a significantly lower footprint than conventional textiles.
BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programmes from early discovery towards clinical phases. With several successful collaborations with leading pharmaceutical organisations, we are also the only AI-drug discovery company with a clinically validated approach, having discovered a leading repurposed drug candidate for COVID-19. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 world-leading scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic.
AIM ImmunoTech Inc., an immuno-pharma company headquartered in Ocala, Florida, is focused on the research and development of therapeutics to treat multiple types of cancers, as well as immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases. AIM ImmunoTech’s flagship products include Ampligen® (Rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon N Injection® (Interferon Alfa-N3). Ampligen® represents an RNA being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen® is also being evaluated for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Alferon N Injection® is approved for a category of STD infection and patients that are intolerant to recombinant interferon in Argentina. Alferon is the only natural-source, multi-species alpha interferon currently approved for sale in the U.S. for the intralesional treatment of refractory (resistant to other treatment) or recurring external Condylomata Acuminata/genital warts (GW) in patients 18 years of age or older. We operate a 30,000-square-foot facility in New Brunswick, NJ to produce Ampligen® and Alferon®. We are committed to a focused business plan oriented toward finding senior co-development partners with the capital and expertise needed to commercialize the many potential therapeutic aspects of Ampligen® and our FDA-approved drug Alferon® N.
EncrypGen makes next-generation software to aide in safely storing and sharing genomic data for research and science, and to allow users to manage their own data and sell it to researchers.
In a vast, unexplored virtual chemical space, Deep Apple Therapeutics moves with unprecedented speed to discover novel small molecules for high-value targets. Deep Apple combines ensemble cryo-EM to explore receptor conformations; deep learning; and the docking of multi-billion compound libraries generated using the company's proprietary Orchard.ai™ algorithm. Deep Apple's deep learning discovery engine is built upon founder expertise in computational modeling, protein and target structure determination, large-scale molecular docking, and the elucidation of protein dynamics and conformational transitions. This structure-based, machine-learning driven drug design approach enables the company to rapidly advance novel candidates addressing well-validated targets in inflammatory, metabolic, and endocrine diseases. For more information, visit deepappletx.com.
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 52,000 employees serve over 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at www.boehringer-ingelheim.com
Epicore Biosystems, Inc. has developed a proprietary sweat microfluidic sensing platform that is ‘skin-like’, low-cost, and capable of analyzing small droplets of sweat directly from the skin. This technology is based on over two decades of microfluidic and soft materials research in Prof. John Rogers' Laboratory at Northwestern University's Center for Bio-Integrated Electronics. Epicore Biosystems recently signed a partnership with a leading Fortune 100 global brand to commercialize the first-ever, single-use sweat analytics system for athletes. The company’s sweat microfluidic platform has been deployed with professional sports teams (NBA, NFL, and MLB), military research labs, and across multiple clinical study programs, including stroke, skin health, stress, fatigue, and kidney health.
Velia is an emerging biotech harnessing the broad therapeutic potential of a newly identified, yet abundant class of human proteins. Transformational work from Velia founders revealed that many of those previously overlooked proteins regulate biological functions vital to human health. Velia will discover and develop therapeutics targeting these novel regulators.
BioMADE is a new Manufacturing Innovation Institute sponsored by the U.S. Department of Defense. BioMADE is building a sustainable, domestic, end-to-end bioindustrial manufacturing ecosystem to secure America’s future through innovation, education, and collaboration. As an independent nonprofit, public-private partnership, BioMADE has the mission and flexibility to propel new biotechnology products from the laboratory to the commercial market.
ARUP Laboratories is a national clinical and anatomic pathology reference laboratory and a worldwide leader in innovative laboratory research and development. A nonprofit enterprise of the University of Utah, ARUP offers an extensive test menu of highly complex and unique medical tests.
Q-State Biosciences is a discovery technology and therapeutics company based in Cambridge, MA, that combines advanced human cellular models, unique measurement engineering and AI / machine learning into a proprietary platform that enables novel discovery of optimized genetically targeted medicines for epilepsy, pain, and other diseases of the CNS.
At Karuna, our purpose is to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Through the cultivation of our deep expertise in neuroscience, and inventive thinking around drug discovery and development, we are advancing a pipeline of novel medicines with the goal of providing a meaningful difference in the lives of those affected by these conditions. Our culture is defined by our passion to serve those affected by mental illness. We are purpose-driven and intentional. We know impactful innovations don’t come easy, but are borne from passion and hard work. Together, we are working toward a goal bigger than ourselves.
We are designing RNA for next generation biomanufacturing and smart therapeutics. https://wayfinderbio.com
Denovo Biopharma is a privately held biotech company providing a novel biomarker solution to personalize drug development.
Circle Pharma initiated operations in June 2014 with seed funding from Pfizer, Inc. and Mission Bay Capital, LLP; we received additional seed funding from ShangPharma Investment Group Limited in November 2015. We recently raised Series B and Series C financing from The Column Group and NextTech Invest. We design and develop bioavailable macrocyclic peptide therapeutics against important clinical targets. We do this by applying a computational structure-based design approach that combines physics (conformational modeling), chemistry (innovative molecular components) and biology (protein target structure and function). We have selected intracellular protein-protein interactions that play key roles in cancer as the initial target group for our internal pipeline development. Circle is taking a new approach to the development of macrocylic peptide therapeutics that is based on the pioneering work of its founders to understand and computationally predict drug-like properties of macrocycles. Circle is advancing this understanding to design novel, inherently permeable macrocyclic peptide drug candidates against Circle’s internal targets and those of our collaboration partners. Our workflow includes the use of proprietary algorithms to design large, conformationally diverse, virtual libraries of cell permeable macrocyclic scaffolds that incorporate natural and non-natural backbone components. We deploy these virtual scaffold libraries in subsequent design steps that include the incorporation of functional side chains selected for both target binding and maintenance of permeability. Candidate compounds are synthesized and tested for both permeability and target affinity and the results are used to inform subsequent design cycles.
GenWay Biotech provides customers with an extensive offering of antibodies, proteins and other reagents for research use only.
Sigenics was established in December 2000 with one purpose in mind: to provide excellence in silicon. In the beginning, Sigenics’ goal was to develop silicon devices to aid in biomedical research. We have grown to become a designer and supplier of “private-label” silicon chips for Original Equipment Manufacturers (OEM) of electronic equipment in multiple markets including: medical, aerospace, industrial, and military. Today, Sigenics Inc. is an ISO 9001:2015 certified company that specializes in designing, testing and delivering custom integrated circuits for sensor, analog and mixed-signal applications. Here at Sigenics we pride ourselves on transforming ideas into realities. Sigenics enhances the value of customers’ products at every phase - specification, design, simulation, layout, and testing - and continues this process until the products’ requirements are satisfied. Privately-held, Sigenics is headquartered in Chicago,IL with an additional design office in Los Osos, CA.
